A study with platinum-resistant ovarian and breast cancer patients with three or more chemotherapy regimens for metastatic disease, all carrying BRCA1/2 mutations, showed a 31.1% and 12.9% tumor response rate to olaparib, indicating that olaparib may indeed be more effective in ovarian than breast cancer (Kaufman et al. 2015). The gene discussed is BRCA1; the disease is breast cancer.